Recently, Yichang Renfu Pharmaceutical Co., Ltd. received the Drug Registration Certificate for its rivastigmine transdermal patch from the National Medical Products Administration. This product was approved for marketing under the category of Class 4 chemical drugs, with specifications of 4.6mg/24 hours and 9.5mg/24 hours, deemed to have passed the consistency evaluation. The rivastigmine transdermal patch is the company's first approved patch, and the approved indication is for the treatment of symptoms of mild to moderate Alzheimer's disease.

Rivastigmine is a carbamate-type, brain-selective acetyl- and butyrylcholinesterase inhibitor. Its mechanism of action is to slow the degradation of acetylcholine released by functionally intact cholinergic neurons, thus contributing to cholinergic neurotransmission. Data from animal studies suggest that Alzheimer's disease is associated with cholinergic-mediated cognitive deficits, and rivastigmine may selectively increase the expression of acetylcholine in the cerebral cortex and hippocampus, potentially improving cholinergic-mediated cognitive deficits.

The launch of the rivastigmine transdermal patch further enriches the company's product line, providing a new option for a wide range of Alzheimer's disease patients. The company will actively promote the marketing and sales of this product.